-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Biogen, Raises Price Target to $225

Benzinga·07/30/2026 15:41:26
Listen to the news
TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $215 to $225.